Skip to main content

Table 1 Baseline characteristics of the enrolled patients with hepatocellular carcinoma at substage B2

From: A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma

N = 31

na (% or range)

Age (years)

 Median (range)

77 (57–86)

Sex

 Male

29 (94)

 Female

2 (6)

Body weight

  ≥ 60 kg

17 (55)

  < 60 kg

14 (45)

Etiology

 HBV

3 (10)

 HCV

6 (19)

 Alcohol

9 (29)

 Other

13 (42)

Child–Pugh score

 5

20 (64)

 6

11 (36)

Maximum diameter of liver tumor (mm)

 Median (range)

36 (10–135)

Liver tumor number

  < 10

23 (74)

 ≧10

8 (26)

Prior history of therapy

 Yes

14 (45)

 No

17 (55)

Blood albumin (g/dL)

 Median (range)

3.9 (3.2–4.7)

Total bilirubin (mg/dL)

 Median (range)

1.0 (0.9–1.0)

Platelet count (× 104 /μL)

 Median (range)

14.2 (6.4–37.8)

α-fetoprotein (ng/mL)

 Median (range)

52.1 (2.4–49,800)

  1. an is the number of patients corresponding to the category of each baseline item, or is the median value of each item. Numbers in parenthesis denote percentages or ranges depending on the variable attributes